vimarsana.com

Latest Breaking News On - Martin heidecker - Page 1 : vimarsana.com

Investegate |PureTech Health PLC Announcements | PureTech Health PLC: Vedanta Gets $106M+ to Advance Microbiome Pipeline

Investegate announcements from PureTech Health PLC, Vedanta Gets $106M+ to Advance Microbiome Pipeline

United kingdomSouth koreaUnited statesBharatt chowriraChristopher viehbacherNeil tiwariwillBernat olleCurt labelleAtlantic neptuneEntityvedanta biosciencesMartin heideckerJournal of the american medical associationPuretech healthBiogen incDepartment of healthKorea investment securities us inc

PureTech Founded Entity Vedanta Biosciences Announces $106 5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023 Funds will also support Phase 2 study of VE202 for ulcerative colitis, to begin in 2Q. | April 25, 2023

United statesSouth koreaUnited kingdomMartin heideckerAtlantic neptuneCurt labelleBernat olleChristopher viehbacherBharatt chowriraNeil tiwariDepartment of healthKorea investment securities us incBiomedical advanced researchDevelopment authorityJournal of the american medical associationPuretech health

AMR Action Fund Announces Investment in BioVersys AG

/PRNewswire/ The AMR Action Fund, the world s largest public-private partnership investing in biotech companies that are developing antimicrobials,.

United statesMarc gitzingerHenry skinnerMartin heideckerEli lillyChris sweeneyUs centers for diseaseAction fundBoehringer ingelheimMerck kgaInternational federation of pharmaceutical manufacturers associationsEuropean commission under horizonEuropean unionNovo nordisk foundationEuropean investment bankWorld health organization

BioVersys Extends its Series C Round to CHF 32 6 Million with Investment from the AMR Action Fund

BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investmentBASEL, Switzerland, January 05, 2023 / B3C newswire / BioVersys AG, a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research a.

Marc gitzingerCarly levineMartin heideckerEliane schmidtSeng chin mahUniversity of lilleAction fundChief executive officerChief investment officerExecutive assistantFinancial managementInfectious disease medicineBacterial infectionsAnti bacterial agentsCritical careDrug resistance

AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesHenry skinnerGreg merrilMartin heideckerBill burnsEli lillyChris burnsUs centers for diseaseAction fundBoehringer ingelheimDeerfield management companyInternational federation of pharmaceutical manufacturersMerck kgaInternational federation of pharmaceutical manufacturers associationsEuropean commission under horizonEuropean union

vimarsana © 2020. All Rights Reserved.